Aktis Oncology (AKTS US) delivered a strong debut to kick off the 2026 IPO market, marking a clear win for both new issuance and the biotech sector. The deal was upsized to 17.65 million shares ahead of pricing, ultimately pricing at the top of the range at $18.00. Shares opened at $27.00, representing an immediate 50% gain, and traded as high as $29.16 ...
Subscribe in seconds and receive IPO Boutique's news feed updates in your inbox, on your phone or even read them from your own news page here on follow.it.
You can select the updates using tags or topics and you can add as many websites to your feed as you like.
And the service is entirely free!
Follow IPO Boutique: IPO Boutique
